The fluoroquinolone antibacterial family is a relatively recent group of bactericidal compounds, generally characterized by efficacy against a wide spectrum of bacterial organisms and exhibiting minimal adverse effects in treated patients. The fluoroquinolones are widely prescribed in both human and veterinary medicine, though in veterinary medicine in the USA there are currently only two approved compounds, enrofloxacin (Baytril 1 , Bayer Animal Health, Shawnee Mission, KS) and sarafloxacin (SaraFlox 1 , Abbott Laboratories, North Chicago, IL), both with limited species and disease label approvals. Currently, there are no approved fluoroquinolone antibacterials to treat bacterial infectious diseases in cultured fish species. Enrofloxacin was administered to juvenile Atlantic salmon as a single bolus via intraarterial (i.a.), intraperitoneal (i.p.), intramuscular (i.m.), or oral gavage routes of administration. The drug was administered via the first three routes to achieve a dose of 10 mg/kg, and via oral gavage to achieve both 10 (p.o.-10) and 5 (p.o.-5) mg/kg doses. Two-compartment model kinetics were observed with elimination of half-lives (t 1/2 ) of 130.6, 34.32, 84.98, 105.11, and 48 .24 h, area under the drug concentration-time curves (AUC) of 84.3, 75.31, 55.61, 41.68, and 38 .81 mg . h/mL, and bioavailabilities (F) of 100, 89.34, 65.97, 49.44, and 46.04% (i.a., i.p., i.m., p.o.-10, p.o.-5, respectively) . All administration routes at 10 mg/kg were found to yield comparable drug concentration± time curves for multiple tissue, indicating no distinct advantage of using one route over another from a kinetics perspective. Finally, the 5 mg/kg dose (p.o.-5) yielded comparable multiple tissue drug concentration±time curves to the 10 mg/kg dose (p.o.-10), providing pharmacokinetic evidence to justify therapeutic efficacy trials with the lower dose.
(Paper received 27 May 1996; accepted for publication 3 August 1996) Most fish and mammalian pharmacokinetic studies have limited their attention to drug determinations in blood. Though blood is the most readily accessible tissue and can be repeatedly sampled over time in larger test subjects, a major limitation inherent in this approach is the failure to investigate drug residue in extravascular spaces, especially problematic in cases where the drug has a high volume of distribution (V d ) and will distribute a significant portion of itself from the`central compartment' to one or several`peripheral compartments'. Clinically, many infectious processes do not limit themselves to the vasculature, so drug presence in a variety of organs and tissues is essential for efficacy. For these reasons, it is essential that the investigator make an extra effort to take additional tissues at harvest including, in the case of food animals,`edible tissues' such as skeletal muscle, milk, and eggs, and visceral tissues such as liver, kidney, etc. to provide a more comprehensive picture of drug distribution. Antibacterial sensitivity and pharmacokinetic data should enable the laboratory or clinical investigator to predict rationally whether efficacy would be attainable in a specified therapeutic situation.
Enrofloxacin is a fluoroquinolone antibacterial compound approved in the USA for use exclusively in dogs and cats. It has a broad spectrum of bactericidal activity including gram-negative bacteria, intracellular organisms such as rickettsia, chlamydia, and mycoplasma, and a lesser spectrum of activity against grampositive organisms. Our laboratory and others have demonstrated enrofloxacin to be efficacious against common and serious bacterial pathogens impacting salmonid culture including Aeromonas salmonicida (causative agent of furunculosis; Bowser et al., 1990; Stoffregen et al., 1993; Bowser et al., 1994; Hsu et al., 1995) , Vibrio anguillarum (agent of vibriosis; Dalsgaard & Bjerregaard, 1991) and Renibacterium salmoninarum (agent of bacterial kidney disease; Hsu et al., 1994) . Previous pharmacokinetic studies of enrofloxacin in finfish have been limited to multiple temperature and dose administration trials in rainbow trout (Bowser et al., 1992) . Other quinolone and fluoroquinolone antimicrobials subject to pharmacokinetic examination in finfish include nalidixic acid (Uno et al., 1992; Jarboe et al., 1993) , oxolinic acid (Bjorklund & Byland, 1991; Hustvedt et al, 1991; Ishida, 1992; Kleinow et al., 1994) , flumequine (Sohlberg et al., 1990; Rogstad et al., 1993) , sarafloxacin (Martinsen et al., 1993a,b; Martinsen et al., 1994) , and difloxacin (Elston et al., 1994) .
This study was performed to compare the administration of single bolus doses of enrofloxacin to juvenile Atlantic salmon by multiple routes of administration and at two potential therapeutic doses (in the case of oral gavage), and subsequently to generate pharmacokinetic data from the resulting drug residue concentrations over a short time interval (5 days) in multiplè edible' and`non-edible' tissues.
M A T E R I A L S A N D M E T H O D S

Animals and chemicals
Juvenile Atlantic salmon (n = 350; mean = 195 g; approximately one year old) and laboratory facilities for the experiments, were generously provided by the Tunison Fish Nutrition Laboratory, National Biological Survey, U.S. Department of the Interior, Cortland, NY. Fish were derived from disease-free broodstock maintained in freshwater on site. Facilities for the experiments consisted of indoors-located concrete raceways supplied with flow-through well water averaging 9.78C consistently throughout the year.
Enrofloxacin (Bayer Animal Health, Inc., Shawnee Mission, KS.) was made available as pure (4 99%) reagent-grade chemical. Aliquots of drug were diluted in 0.05 mM, pH 10.5 phosphate buffer immediately prior to use and were stored in the refrigerator in foil covered bottles to limit the effects of light on the drug.
Experimental design
Groups of fish (n = 75) were lightly anaesthetized, in order to effect dorsal recumbency and cessation of struggling when held, by being submerged in a dilute solution of tricaine methanesulfonate (100 mg drug/3 L water; Sigma Chemical Co., St. Louis, MO). Enrofloxacin solution was injected with 1 cc tuberculin syringes and 22 gauge 6 1 inch hypodermic needles (Becton-Dickinson, Rutherford, NJ) to achieve a dose of 10 mg/ kg by intraarterial (i.a.; dorsal aorta via the oral cavity), intramuscular (i.m.; left side epaxial musculature below dorsal fin), or intraperitoneal (i.p.; fish held in dorsal recumbency, injection to the right of the ventral midline and & 2 cm cranial to the vent with the needle directed cranially) injections. Additional groups (n = 60) were dosed by oral gavage (p.o.) at 10 mg/kg (p.o.-10) or 5 mg/kg (p.o.-5) with an appropriate length stainless steel, laboratory animal oral gavage dosing needle (Popper Co., New York City, NY.).
Fish (n = 5) were scheduled for harvest at 0, 1.2, 2. 4, 6, 12, 18, 30 and 45 min, and 4, 12, 24, 48, 72, 96 and 120 h posttreatment (i.a., i.p., and i.m.) or at 0, 2.4, 12, 30, and 45 min, and 4, 12, 24, 48, 72, 96 and 120 h (both p.o. groups) . At harvest, the fish were lightly anaesthetized to effect dorsal recumbency and cessation of struggling when held (as above) and blood samples acquired via caudal vein venipuncture (Vacutainer 1 22 gauge 6 1 inch single sample needles;
Becton-Dickinson) into Lithium Heparin-coated Vacutainer 1 tubes (Becton-Dickinson). Blood samples were gently inverted several times to facilitate mixing with the anticoagulant and then stored in crushed ice. Following venipuncture, the fish were returned to the anaesthetic solution (as above) to be killed by overdosage (usually 1±2 min immersion required) followed by exsanguination. Carcasses were examined for gross lesions, dissected, and representative quantities (1±3 g) of skeletal muscle with attached skin (taken from right epaxial area adjacent to dorsal fin), liver, kidney, gill, and the entire brain with attached cervical spinal cord were placed in individually marked plastic bags and stored on ice.
Blood samples were centrifuged (International Equipment Company CENTRA 7 1 refrigerated centrifuge, USA) at 2500 r.p.m. for 10 min. Plasma was removed, placed in 1.5 mL Eppendorf vials (Laboratory Products, Inc., Rochester, NY). All tissue samples were stored frozen at ±20 8C until retrieved for assay. Custom constructed 30 cm 6 30 cm glass with aluminum frame bioassay plates were flame sterilized with 95% ethanol and 250 mL of sterilized liquid Mueller-Hinton media (DIFCO Laboratories) solution was poured hot onto the plates. After cooling for 1 h, 8 mm wells were cut into the solidified agar using an 8 mm stainless steel punch, with wells localized with the aid of a paper template located under the glass plates. Samples were individually thawed, weighed, and diluted with three volumes of 50 mM, pH 10.5 sodium bicarbonate buffer. Samples were then homogenized with a Polytron 1 tissue grinder (Brinkmann Instruments, Inc., Westbury, NY). Controls were created using zero-time fish tissues, handled exactly as unknowns, and spiked with serial dilutions of enrofloxacin from 4.0±0.008 mg/mL (p.p.m.). Aliquots (90 mL) of prepared samples were pipetted into the bioassay plate wells, glass lids were secured to the plates and sealed with masking tape, and these sealed plates were incubated overnight at room temperature. The following morning plates were placed in a 37 8C microbiology incubator for 6 h. At that time, diameters of the resultant zones of inhibition were read with electronic digital calipers. All samples including controls were run in triplicate.
Antimicrobial assay
Control drug concentration vs. zone of inhibition plots were produced for each tissue on semi-logarithmic graphs, and regression lines generated using Cricket 1 graphing software (International Associates, Islandia, NY). These regression lines served as the means of interpretation of the experimental tissue sample zones of inhibition. Data was compiled for each time point (mean, standard deviation) and plotted semi-logarithmically to determine the time course of tissue-specific drug residue depletion.
Pharmacokinetic analysis
Pharmacokinetic compartmental and non-compartmental modelling of the drug concentration-time data was performed with the aid of R-STRIP 1 Polyexponential Curve Stripping/Parameter Estimation software, Version 5.0 (MicroMath Scientific Software, Salt Lake City, UT.). Biexponential modelling of distribution and elimination (i.a.) or absorption and elimination (i.p., i.m., p.o.-10, and p.o.-5) involved an initial stripping of the data, followed by best-fitting the data, and the subsequent generation of appropriate statistics. Data stripping and fitting involved lessening the weighted sum of squares, maximizing the correlation (r) and coefficient of determination (r 2 ) statistics, and using weighing factors (1/y**W.F.; W.F.in the range of 0±2) as necessary to optimize curve fitting to the data points. Parameters ), f ss (fraction of steady-state achieved upon repetitive dosing = AUC 0-t /AUC0±4), C ss,av (mean plasma drug concentration at steady-state = AUC/dosing interval (assuming the dosing interval was 24 h)), C 24 (drug concentration at 24 h), and F (bioavailability = AUCother route/AUCi.a.).
R E S U L T S
All trials were run with sequential sampling (n = 5) through 120 h (with the exception of the i.p. trial which had the final sample deleted due to an unanticipated severe winter snowstorm). Tissue drug concentrations and standard deviations at the sequential time points are displayed semi-logarithmetically for the i.a., i.p., i.m., p.o.±10 mg, and p.o.±5 mg trials in Figs 1± 5. Tissue drug C max and t max were determined by examination of the tabulated raw data, and are presented as mean (0) and standard deviations (SD) in Table 1 . Regarding the`edible' tissues (skeletal muscle and skin), these data generally demonstrate higher drug concentrations but similar peak concentration times for the parenteral routes vs. the enteral drug administrations. Skin and kidney drug concentrations increased with time, while the other tissue concentrations either decreased or reached a plateau for the duration (120 h) of this experiment.
When the drug concentration±time data was stripped and fitted with nonlinear regression, biexponential kinetic models were generally optimal for all tissues, routes of administration, and drug doses. Semi-logarithmetic plasma concentration±time with superimposed nonlinear-fitted curves for each route and dose are presented in Fig. 6 . Compartmental and non-compartmental parameters calculated for the multiple tissues examined are presented for the parenteral routes of administration in Table  2 and for the enteral route (with two doses) in Table 3 . The i.a. study revealed a V d(area) = 22.36 L/kg, a MRT = 181.5 h, an AUC (0-? ) = 84.3 mg . h/mL, and a Cl = 118.6 mL/h . kg. Tissue drug C max was detected in the gill and kidney (14.38 + 3.69 and 13.87 + 2.79 mg/g) at a t max of 19.35 + 42.85 and 91.2 + 26.29 h, respectively. The i.p. study revealed a V d(area) = 6.577 L/kg, a MRT = 49.76 h, an AUC = 75.31 mg . h/mL, a Cl = 132.8 mL/h . kg, and a calculated bioavailability (F) of 89.34%. Tissue drug C max was detected in the kidney and liver (21.14 + 2.93 and 11.04 + 2.19 mg/g) at a t max of 100.8 + 85.52 and 0.42 + 0.11 h, respectively. The i.m. route had a V d(area) = 22.04 L/kg, a MRT = 122.6 h, an AUC = 55.61 mg . h/mL, a Cl = 179.8 mL/h . kg, and a F = 65.97%. Tissue drug C max was detected in kidney and skin (17.58 + 2.94 and 16.64 + 6.36 mg/g) at a t max of 91.2 + 20.07 and 0.10 + 0.12 h, respectively.
The p.o.-10 gavage study had a MRT = 151.69 h, an AUC = 41.68 mg . h/mL, and a bioavailability of 49.44%. Tissue drug C max was detected in kidney and gill (9.23 + 1.94 and 5.04 + 3.97 mg/g) at a t max of 105.6 + 13.15 and 0.32 + 0.16 h, respectively. The p.o.-5 gavage trial had a MRT = 70.20 h, and AUC = 38.81 mg . h/mL, and a F = 46.04%. Tissue drug C max was detected in gill and kidney (16.97 + 8.54 and 5.70 + 1.32 mg/g) at a t max of 0.14 + 0.09 and 86.4 + 40.16 h, respectively.
D I S C U S S I O N
Efficacy of an antimicrobial drug to treat infectious disease in any animal has two basic requirements for success. First, the concentration of drug in the immediate environment of the microbe should equal the minimal bactericidal concentration (MBC) or exceed the minimal inhibitory concentration (MIC). Secondly, the pharmacokinetics of the potential chemotherapeutic must be such that the drug is adequately absorbed (if given via enteral or non-intravascular parenteral routes), distributed to sites of the body likely to be inhabited by the disease-causing microbe, biotransformed either to a less active entity at a rate compatible with effective action or biotransformed to a greater ac-tivity metabolite without significant host toxicity, and ultimately eliminated at a rate and via a route compatible with host safety.
Our trials directly compared multiple routes of enrofloxacin administration and two doses by the oral gavage route in Atlantic salmon juveniles. This is the first time that variable routes and doses have been examined in this species. It is also the first time that multiple tissues (seven) have been analysed for drug content as a function of time following single administrations of a chemotherapeutic, and subsequently subjected to nonlinear regression-based data stripping and fitting and subsequent pharmacokinetic parameter estimation.
Our data demonstrates a remarkable overall similarity regarding tissue drug residue concentration±time in multiple tissues, whether drug is administered via the parenteral (intravascular, intraperitoneal, and intramuscular) or enteral (oral gavage) routes of administration. These similarities probably reflect the inherent lipophilicity and the resultant high volume of distribution (V d ) of this compound, along with generally high bioavailabilities from parenteral and enteral administration sites. Tissues generally demonstrated similar patterns of a slight residue depletion or a plateauing effect over our 120 h time course, with the exception of kidney and skin with attached fat which generally demonstrated an increase of drug residue with time. The latter point is comparable with our field trial experiences (Stoffregen et al., 1993; Stoffregen, 1995) in which skin was slow to deplete residue, and kidney often retained residue for extended periods of time. This information would support our hypothesis that enrofloxacin is redistributing over time to tissues with extensive fat (skin) or connective tissue (kidney, skin) components, which are acting as a`drug sink'.
Regarding the 5 and 10 mg/kg p.o. gavage trials specifically, drug residues in all tissues analyzed seem remarkably similar at both doses with only minimally higher C max for residues in four of seven tissues (skeletal muscle, skin, liver, and kidney) and slightly shorter t max for the first three tissues at the higher dose. This similar data in both`edible' and`inedible' tissues justifies decreasing our present clinical dose of 10 mg/kg/d ±1 to a new lower trial dose of 5 mg/kg/d ±1 (both administered via medicated feed), which could effectively decrease by half the quantity of drug needed for treatment of schools of cultured fish, thereby decreasing cost of medication (and subsequent formulation in feed) to the producer and lessening the potential environmental impact of drug, both as a result of less medication in feed entering the water and less production of fish fecal waste contaminated with drug and/or metabolite residue. Laboratory-based pharmacokinetic trials may be imperfect models of the field treatment of populations of sick fish, which practically can only be treated en mass by medicated feed or bath treatments (i.e. individual fish treatments are impossible because of the population numbers involved). While treatment of fish populations are the norm, single fish parenteral or enteral routes may be appropriate in limited circumstances such as when treating valuable broodstock or small populations of fish, either therapeutically or prophylactically. Our purpose in performing these studies was not to emulate field treatment protocols, but instead to examine single-dose, multiple-route enrofloxacin pharmacokinetics using a limited group of study animals and to gain the maximum information possible from each animal. To this end, these studies administered known quantities of drug via well defined, repeatable routes of administration, and demonstrated that all of these routes tested appear to yield comparable quantities of drug residue in multiple tissues. Most significantly, this data may serve as a baseline with which to compare pharmacokinetic parameters from future laboratory and fieldstudy feeding trials, to assess whether the target populations are receiving adequate medication for their therapeutic needs.
The enrofloxacin depletion from plasma of the Atlantic salmon, following both i.a. (10 mg) and p.o. gavage (5 and 10 mg doses), appears similar to results reported in administering 5 and 10 mg enrofloxacin/kg to the rainbow trout at 108C (Bowser et al., 1992) . This comparable data may serve to support the concept of`species grouping' by regulatory officials, i.e. allowing data gathered from one or multiple salmonid species to be collated and eventually to serve as the basis to allow à salmonid' approval of enrofloxacin or any other chemotherapeutic. This would certainly expedite the regulatory review and approval process, and allow producers and aquaculture-service veterinarians effectively to treat disease processes from which they are currently legally prohibited.
Currently, fluoroquinolones approved for veterinary medicine are limited to Baytril 1 for dogs and cats (approved in, 1989) and SaraFlox WSP 1 for broiler chickens and turkeys (approved in August, 1995) . Several other fluoroquinolone food animal applications have been in the review process by the Center for Veterinary Medicine at the FDA for several years. An ongoing concern of infectious disease regulatory officials has been that fluoroquinolone use in veterinary medicine would lead to the emergence of fluoroquinolone-resistance, thus eliminating a critically important antibacterial class necessary to treat many serious and potentially life-threatening human bacterial diseases. A joint veterinary medicine advisory committee and antiinfective drugs advisory committee meeting on the topic of Fluoroquinolones in Food Animal Medicine in 1994 addressed these concerns, resulting in a Fluoroquinolone Working Group Report for the FDA/CVM in 1995, which among other findings recommended`fluoroquinolones intended for use in food animals can be approved without categorical restriction (i.e. by dosage form, species, production class, or production environment)'. In the autumn of 1995, the FDA formally banned extra-label use of fluoroquinolones in all food-producing animal species (Gleed, 1996) , including administration via medicated feed in the ban. Fluoroquinolones must now be specifically approved for each food-producing species, specific disease indications, and by specific routes of administration. While several quinolones and fluoroquinolones have been investigated in various fish species (Stoffregen et al., 1996) , enrofloxacin and sarafloxacin have been most thoroughly and favourably reported in the international fish health literature, and appear to be the best current candidates for eventual fish health approvals in the USA. Direct comparisons of enrofloxacin and sarafloxacin have been limited to MIC determinations for specific bacterial pathogens and a single-dose pharmacokinetic study in Atlantic salmon. Generally, enrofloxacin has shown superior MICs to those of sarafloxacin including tests of oxolinic acid-susceptible and -resistant isolates of Aeromonas salmonicida strains (Barnes et al., 1990) and multiple isolates of A. salmonicida ssp. salmonicida, atypical A. salmonicida, Vibrio anguillarum, Vibrio salmonicida, and Yersinia ruckeri (Martinsen et al., 1992) . In a comparative pharmacokinetic experiment in juvenile Atlantic salmon in seawater at 108C given single doses of drug at 10 mg/kg, enrofloxacin had superior bioavailability compared to sarafloxacin; 55.5% vs. 2.2%, respectively (Martinsen & Horsberg, 1995) . No direct comparative field trials of the two compounds in either healthy or ill fish have occurred to the authors' knowledge.
Enrofloxacin has repeatedly demonstrated good to excellent efficacy in treating common infectious bacterial diseases of salmonids in laboratory-based in vitro MIC generation, dose titration, and pharmacokinetic experiments, and this data has been supported by field trials treating clinically ill fish populations. The data generated from our experiments leads to the conclusion that enrofloxacin has demonstrated the ability to widely distribute to diverse tissues for prolonged time periods where bacterial pathogens may be encountered in a variety of generalized (septicemic) or localized disease processes. 
